NICE gives RoActemra a second chance - update
This article was originally published in Scrip
Executive Summary
The National Institute for Health and Clinical Excellence (NICE), the health technology assessment body for England and Wales, says that with extra data from Roche it might recommend RoActemra (tocilizumab) for some NHS patients with rheumatoid arthritis in its final guidance.